#Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial
1	1	0	10	Doravirine
1	2	11	15	dose
1	3	16	25	selection
1	4	26	29	and
1	5	30	37	96-week
1	6	38	44	safety
1	7	45	48	and
1	8	49	57	efficacy
1	9	58	64	versus
1	10	65	74	efavirenz
1	11	75	77	in
1	12	78	92	antiretroviral
1	13	93	106	therapy-naive
1	14	107	113	adults
1	15	114	118	with
1	16	119	124	HIV-1
1	17	125	134	infection
1	18	135	137	in
1	19	138	139	a
1	20	140	145	Phase
1	21	146	149	IIb
1	22	150	155	trial
#BACKGROUND: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection (NCT01632345).
2	1	156	166	BACKGROUND
2	2	166	167	:
2	3	168	171	The
2	4	172	178	safety
2	5	179	182	and
2	6	183	191	efficacy
2	7	192	194	of
2	8	195	205	doravirine
2	9	206	210	were
2	10	211	219	compared
2	11	220	224	with
2	12	225	229	that
2	13	230	232	of
2	14	233	242	efavirenz
2	15	243	245	as
2	16	246	253	initial
2	17	254	263	treatment
2	18	264	266	of
2	19	267	273	adults
2	20	274	280	living
2	21	281	285	with
2	22	286	291	HIV-1
2	23	292	301	infection
2	24	302	303	(
2	25	303	314	NCT01632345
2	26	314	315	)
2	27	315	316	.
#METHODS: A Phase IIb double-blind trial with participants stratified by screening HIV-1 RNA (≤ or >100,000 copies/ml) and randomized 1:1:1:1:1 to receive once-daily doravirine (25, 50, 100 or 200 mg) or efavirenz 600 mg (Part I) for up to 96 weeks, with open-label tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC).
3	1	478	485	METHODS
3	2	485	486	:
3	3	487	488	A
3	4	489	494	Phase
3	5	495	498	IIb
3	6	499	511	double-blind
3	7	512	517	trial
3	8	518	522	with
3	9	523	535	participants
3	10	536	546	stratified
3	11	547	549	by
3	12	550	559	screening
3	13	560	565	HIV-1
3	14	566	569	RNA
3	15	570	571	(
3	16	571	572	≤
3	17	573	575	or
3	18	576	577	>
3	19	577	584	100,000
3	20	585	594	copies/ml
3	21	594	595	)
3	22	596	599	and
3	23	600	610	randomized
3	24	611	620	1:1:1:1:1
3	25	621	623	to
3	26	624	631	receive
3	27	632	642	once-daily
3	28	643	653	doravirine
3	29	654	655	(
3	30	655	657	25
3	31	657	658	,
3	32	659	661	50
3	33	661	662	,
3	34	663	666	100
3	35	667	669	or
3	36	670	673	200
3	37	674	676	mg
3	38	676	677	)
3	39	678	680	or
3	40	681	690	efavirenz
3	41	691	694	600
3	42	695	697	mg
3	43	698	699	(
3	44	699	703	Part
3	45	704	705	I
3	46	705	706	)
3	47	707	710	for
3	48	711	713	up
3	49	714	716	to
3	50	717	719	96
3	51	720	725	weeks
3	52	725	726	,
3	53	727	731	with
3	54	732	742	open-label
3	55	743	752	tenofovir
3	56	753	763	disoproxil
3	57	764	772	fumarate
3	58	773	776	300
3	59	777	793	mg/emtricitabine
3	60	794	797	200
3	61	798	800	mg
3	62	801	802	(
3	63	802	809	TDF/FTC
3	64	809	810	)
3	65	810	811	.
#After dose selection at week 24, doravirine 100 mg was provided to participants receiving the other doses of doravirine and additional participants were randomized 1:1 to receive once-daily doravirine 100 mg or efavirenz 600 mg for 96 weeks with TDF/FTC
4	1	1146	1151	After
4	2	1152	1156	dose
4	3	1157	1166	selection
4	4	1167	1169	at
4	5	1170	1174	week
4	6	1175	1177	24
4	7	1177	1178	,
4	8	1179	1189	doravirine
4	9	1190	1193	100
4	10	1194	1196	mg
4	11	1197	1200	was
4	12	1201	1209	provided
4	13	1210	1212	to
4	14	1213	1225	participants
4	15	1226	1235	receiving
4	16	1236	1239	the
4	17	1240	1245	other
4	18	1246	1251	doses
4	19	1252	1254	of
4	20	1255	1265	doravirine
4	21	1266	1269	and
4	22	1270	1280	additional
4	23	1281	1293	participants
4	24	1294	1298	were
4	25	1299	1309	randomized
4	26	1310	1313	1:1
4	27	1314	1316	to
4	28	1317	1324	receive
4	29	1325	1335	once-daily
4	30	1336	1346	doravirine
4	31	1347	1350	100
4	32	1351	1353	mg
4	33	1354	1356	or
4	34	1357	1366	efavirenz
4	35	1367	1370	600
4	36	1371	1373	mg
4	37	1374	1377	for
4	38	1378	1380	96
4	39	1381	1386	weeks
4	40	1387	1391	with
4	41	1392	1399	TDF/FTC
#(Part II)
5	1	1654	1655	(
5	2	1655	1659	Part
5	3	1660	1662	II
5	4	1662	1663	)
#.
6	1	1673	1674	.
#Primary outcomes were the proportion of participants with HIV-1 RNA <40 copies/ml at week 24, and central nervous system (CNS) adverse events (AEs) by weeks 8 and 24 (Parts I+II combined).
7	1	1677	1684	Primary
7	2	1685	1693	outcomes
7	3	1694	1698	were
7	4	1699	1702	the
7	5	1703	1713	proportion
7	6	1714	1716	of
7	7	1717	1729	participants
7	8	1730	1734	with
7	9	1735	1740	HIV-1
7	10	1741	1744	RNA
7	11	1745	1746	<
7	12	1746	1748	40
7	13	1749	1758	copies/ml
7	14	1759	1761	at
7	15	1762	1766	week
7	16	1767	1769	24
7	17	1769	1770	,
7	18	1771	1774	and
7	19	1775	1782	central
7	20	1783	1790	nervous
7	21	1791	1797	system
7	22	1798	1799	(
7	23	1799	1802	CNS
7	24	1802	1803	)
7	25	1804	1811	adverse
7	26	1812	1818	events
7	27	1819	1820	(
7	28	1820	1823	AEs
7	29	1823	1824	)
7	30	1825	1827	by
7	31	1828	1833	weeks
7	32	1834	1835	8
7	33	1836	1839	and
7	34	1840	1842	24
7	35	1843	1844	(
7	36	1844	1849	Parts
7	37	1850	1854	I+II
7	38	1855	1863	combined
7	39	1863	1864	)
7	40	1864	1865	.
#RESULTS: 210 and 132 participants were randomized in Parts I and II, respectively, and 216 (108 on doravirine 100 mg, 108 on efavirenz) were evaluable for Parts I+II combined.
8	1	2055	2062	RESULTS
8	2	2062	2063	:
8	3	2064	2067	210
8	4	2068	2071	and
8	5	2072	2075	132
8	6	2076	2088	participants
8	7	2089	2093	were
8	8	2094	2104	randomized
8	9	2105	2107	in
8	10	2108	2113	Parts
8	11	2114	2115	I
8	12	2116	2119	and
8	13	2120	2122	II
8	14	2122	2123	,
8	15	2124	2136	respectively
8	16	2136	2137	,
8	17	2138	2141	and
8	18	2142	2145	216
8	19	2146	2147	(
8	20	2147	2150	108
8	21	2151	2153	on
8	22	2154	2164	doravirine
8	23	2165	2168	100
8	24	2169	2171	mg
8	25	2171	2172	,
8	26	2173	2176	108
8	27	2177	2179	on
8	28	2180	2189	efavirenz
8	29	2189	2190	)
8	30	2191	2195	were
8	31	2196	2205	evaluable
8	32	2206	2209	for
8	33	2210	2215	Parts
8	34	2216	2220	I+II
8	35	2221	2229	combined
8	36	2229	2230	.
#At week 24, the proportion of participants with HIV-1 RNA <40 copies/ml was 72.9% for doravirine 100 mg and 73.1% for efavirenz (difference -0.5 [95% CI -12.3, 11.2]).
9	1	2407	2409	At
9	2	2410	2414	week
9	3	2415	2417	24
9	4	2417	2418	,
9	5	2419	2422	the
9	6	2423	2433	proportion
9	7	2434	2436	of
9	8	2437	2449	participants
9	9	2450	2454	with
9	10	2455	2460	HIV-1
9	11	2461	2464	RNA
9	12	2465	2466	<
9	13	2466	2468	40
9	14	2469	2478	copies/ml
9	15	2479	2482	was
9	16	2483	2487	72.9
9	17	2487	2488	%
9	18	2489	2492	for
9	19	2493	2503	doravirine
9	20	2504	2507	100
9	21	2508	2510	mg
9	22	2511	2514	and
9	23	2515	2519	73.1
9	24	2519	2520	%
9	25	2521	2524	for
9	26	2525	2534	efavirenz
9	27	2535	2536	(
9	28	2536	2546	difference
9	29	2547	2551	-0.5
9	30	2552	2553	[
9	31	2553	2555	95
9	32	2555	2556	%
9	33	2557	2559	CI
9	34	2560	2565	-12.3
9	35	2565	2566	,
9	36	2567	2571	11.2
9	37	2571	2572	]
9	38	2572	2573	)
9	39	2573	2574	.
#In addition, CNS AEs were reported by 26.9% and 47.2% of doravirine and efavirenz recipients, respectively (difference -20.4 [95% CI -32.6, -7.5]; P=0.002).
10	1	2743	2745	In
10	2	2746	2754	addition
10	3	2754	2755	,
10	4	2756	2759	CNS
10	5	2760	2763	AEs
10	6	2764	2768	were
10	7	2769	2777	reported
10	8	2778	2780	by
10	9	2781	2785	26.9
10	10	2785	2786	%
10	11	2787	2790	and
10	12	2791	2795	47.2
10	13	2795	2796	%
10	14	2797	2799	of
10	15	2800	2810	doravirine
10	16	2811	2814	and
10	17	2815	2824	efavirenz
10	18	2825	2835	recipients
10	19	2835	2836	,
10	20	2837	2849	respectively
10	21	2850	2851	(
10	22	2851	2861	difference
10	23	2862	2867	-20.4
10	24	2868	2869	[
10	25	2869	2871	95
10	26	2871	2872	%
10	27	2873	2875	CI
10	28	2876	2881	-32.6
10	29	2881	2882	,
10	30	2883	2887	-7.5
10	31	2887	2888	]
10	32	2888	2889	;
10	33	2890	2897	P=0.002
10	34	2897	2898	)
10	35	2898	2899	.
#CONCLUSIONS: Doravirine 100 mg with TDF/FTC demonstrated similar antiretroviral activity and superior CNS safety compared with efavirenz 600 mg with TDF/FTC.
11	1	3057	3068	CONCLUSIONS
11	2	3068	3069	:
11	3	3070	3080	Doravirine
11	4	3081	3084	100
11	5	3085	3087	mg
11	6	3088	3092	with
11	7	3093	3100	TDF/FTC
11	8	3101	3113	demonstrated
11	9	3114	3121	similar
11	10	3122	3136	antiretroviral
11	11	3137	3145	activity
11	12	3146	3149	and
11	13	3150	3158	superior
11	14	3159	3162	CNS
11	15	3163	3169	safety
11	16	3170	3178	compared
11	17	3179	3183	with
11	18	3184	3193	efavirenz
11	19	3194	3197	600
11	20	3198	3200	mg
11	21	3201	3205	with
11	22	3206	3213	TDF/FTC
11	23	3213	3214	.
